EASL Studio S6 E15: What‘s hot in viral hepatitis in 2024?

EASL Studio S6 E14: Endohepatology: The endoscopic liver gold rush

EASL Studio S6 E13: Resmetirom: First approved drug for MASH, for whom and for how long?

EASL Studio S6 E12: Do we care enough about the importance of DILI/DHILI ?

EASL Studio S6 E11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?

EASL Studio S6 E10: YI Choice: Citizen science: Societal engagement in hepatology

EASL Studio S6 E9: Therapy hierarchy in HCC: A new kid on the block

EASL Studio S6 E8: Is there a role for measuring blood ammonia in patients with cirrhosis?

EASL Studio S6 E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study

EASL Studio S6 E6: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

EASL Studio S6 E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?

EASL Studio S6 E4: World Cholangiocarcinoma Day: Highlighting guidelines and exploring the horizon beyond

EASL Studio S6 E3: How to stop recurrent bleeding due to small-intestinal angiodysplasia?

EASL Studio S6 E2: Why do we need HBV functional cure?

EASL Studio S6 E1: Do we solve MASLD by treating obesity?